<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03861364</url>
  </required_header>
  <id_info>
    <org_study_id>2019/375</org_study_id>
    <secondary_id>2019-000958-56</secondary_id>
    <nct_id>NCT03861364</nct_id>
  </id_info>
  <brief_title>Hemodynamics During Induction of General Anesthesia With High and Low Propofol Dose.</brief_title>
  <acronym>PH</acronym>
  <official_title>Haemodynamic Stability During Induction of General Anesthesia With Propofol and Remifentanil: A Randomized, Controlled, Double-blind Study Comparing Low vs High Propofol Doses.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Fonna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helse Fonna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to examine if a high propofol dose is non-inferior to a low dose in
      respect to hemodynamic stability in healthy patients during induction of general anesthesia
      with propofol and remifentanil.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Typically, one or more adjuvant medications are administered to supplement induction of
      general anesthesia. When combining anesthetic drugs, the hypnotic effects are often
      synergistic. Propofol is associated with hypotension and bradycardia and used together with
      remifentanil or sedative agents it may give synergistic or additive sedative and hemodynamic
      effects.

      Claeys (1988) and Fairfield (1991) examined the cardiovascular effects of propofol 2-2.5
      mg/kg induction dose and found significant reductions i SBP and SVR and small changes in CO,
      SV and HR. De Wit (2016) examined hemodynamic changes in different steady state propofol
      serum concentrations, and found a dose dependent SBP reduction, reduction in resistance of
      arterial and systemic circulation and a reduction in mean systemic filling pressures (MSFP)
      indicative of a reduction in &quot;stressed volumes&quot;. The effective dose (ED) 95% for loss of
      consciousness for propofol was determined to 1.75 mg/kg when used alone, and 1.38 mg/kg when
      used together with remifentanil 0.25 microg/kg/min (total induction dose 1.75 microg/kg
      remifentanil) in a study by Koh et al. We want to examine the hemodynamic effects of giving a
      low (1.4 mg/kg) vs a high (2.4 mg/kg) propofol dose combined with a moderate remifentanil
      dose (about 1.5 microg/kg).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 3, 2019</start_date>
  <completion_date type="Actual">May 31, 2020</completion_date>
  <primary_completion_date type="Actual">May 19, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, controlled, double blind.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomization made by a person not involved in trial in other ways. Allocation masked in sealed envelopes, stored in a locked cash box only opened by two drug preparing nurses not involved in patient care. Syringe labelled with patient identification (ID) (eg 03Prop). Patient, Care Provider and Investigator blinded for actual concentration of drug. Allocation break after data data wash and processing.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic blood pressure (SBP)</measure>
    <time_frame>The first 7.5 minutes during induction of general anesthesia</time_frame>
    <description>Relative change of SBP (mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate (HR)</measure>
    <time_frame>The first 7.5 minutes during induction of general anesthesia</time_frame>
    <description>Relative change of HR (beats)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stroke Volume (SV)</measure>
    <time_frame>The first 7.5 minutes during induction of general anesthesia</time_frame>
    <description>Relative change of SV (ml/beat)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Output (CO)</measure>
    <time_frame>The first 7.5 minutes during induction of general anesthesia</time_frame>
    <description>Relative change of CO (litre/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Vascular Resistance (SVR)</measure>
    <time_frame>The first 7.5 minutes during induction of general anesthesia</time_frame>
    <description>Relative change of SVR (dynes-sec/cm5/m2)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Hemodynamics Instability</condition>
  <condition>Anesthesia, General</condition>
  <condition>Anesthesia, Intravenous</condition>
  <arm_group>
    <arm_group_label>High Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High Propofol induction dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low Propofol induction dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>2,4 mg/kg</description>
    <arm_group_label>High Propofol</arm_group_label>
    <other_name>Propolipid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>1,4 mg/kg</description>
    <arm_group_label>Low Propofol</arm_group_label>
    <other_name>Propolipid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women

          -  Age 18-50 years

          -  Gynecological procedures

          -  General anesthesia

        Exclusion Criteria:

          -  Pre-existing hypertension

          -  Diabetes for several years

          -  Ischemic heart disease

          -  Cerebrovascular disease

          -  Heart valve disease

          -  Verified cardiac arrhythmia

          -  Anaemia

          -  Kidney or hepatic disease

          -  Hypersensitivity for soya, eggs or peanuts

          -  Pregnancy

          -  Poor health state

          -  Illicit substance use

          -  BMI &lt;20 or &gt;35 kg/m2

          -  SBP &gt;150 mmHg

          -  HR &gt;100 beats/min
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar H Sjøen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helse Fonna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kirurgisk Klinikk-Anestesi</name>
      <address>
        <city>Haugesund</city>
        <state>Rogaland</state>
        <zip>5504</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Koh JC, Park J, Kim NY, You AH, Ko SH, Han DW. Effects of remifentanil with or without midazolam pretreatment on the 95% effective dose of propofol for loss of consciousness during induction: A randomized, clinical trial. Medicine (Baltimore). 2017 Dec;96(49):e9164. doi: 10.1097/MD.0000000000009164.</citation>
    <PMID>29245361</PMID>
  </reference>
  <reference>
    <citation>Claeys MA, Gepts E, Camu F. Haemodynamic changes during anaesthesia induced and maintained with propofol. Br J Anaesth. 1988 Jan;60(1):3-9.</citation>
    <PMID>3257393</PMID>
  </reference>
  <reference>
    <citation>Fairfield JE, Dritsas A, Beale RJ. Haemodynamic effects of propofol: induction with 2.5 mg kg-1. Br J Anaesth. 1991 Nov;67(5):618-20.</citation>
    <PMID>1751277</PMID>
  </reference>
  <reference>
    <citation>de Wit F, van Vliet AL, de Wilde RB, Jansen JR, Vuyk J, Aarts LP, de Jonge E, Veelo DP, Geerts BF. The effect of propofol on haemodynamics: cardiac output, venous return, mean systemic filling pressure, and vascular resistances. Br J Anaesth. 2016 Jun;116(6):784-9. doi: 10.1093/bja/aew126.</citation>
    <PMID>27199311</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helse Fonna</investigator_affiliation>
    <investigator_full_name>Gunnar Helge Sjøen</investigator_full_name>
    <investigator_title>Overlege, anestesi</investigator_title>
  </responsible_party>
  <keyword>Cardiac Output (CO)</keyword>
  <keyword>Systolic Blood Pressure (SBP)</keyword>
  <keyword>Systemic Vascular Resistance (SVR)</keyword>
  <keyword>Heart Rate (HR)</keyword>
  <keyword>Stroke Volume (SV)</keyword>
  <keyword>Lithium Dilutional Cardiac Output (LiDCO)</keyword>
  <keyword>Minimal Invasive Hemodynamic Monitor</keyword>
  <keyword>Propofol</keyword>
  <keyword>Propolipid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>LiDCO-csv raw data and processed data will be made public at the publishers site, and the supporting information by request to the Principal Investigator. Statistical Data Plan is included in Study Protocol.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The data will be stored for 15 years after end of study, and may be shared during this time frame.</ipd_time_frame>
    <ipd_access_criteria>The data may be shared by contacting the Principal Investigator.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

